DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1902)

Asthma | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)

Asthma | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance therapy (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort) and rescue therapy (e.g., a SABA, such as albuterol)—and most adult asthma patients receive more than one drug to treat their condition. Although multiple well-established agents are available for both maintenance and rescue treatment, in the past few years, the adult asthma treatment landscape has witnessed the approval of the first branded-generic LABA/ICS FDC (i.e., Teva’s AirDuo and its generic), the first LAMA (i.e., Boehringer-Ingelheim’s Spiriva), and several novel biologics (e.g., GSK’s Nucala, Teva’s Cinqair). The availability of these agents has expanded physicians’ treatment arsenal and fueled increasing competition in the asthma therapy market.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?
  • How have newer adult asthma therapies, such as Spiriva, Nucala, and Cinqair, been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult asthma patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Geographies

  • United States.

Real-World Data

  • Longitudinal patient-level claims data analysis.

Key Drugs Covered

  • Advair, Symbicort, Dulera, Breo, Spiriva, Xolair, Nucala, Cinqair, Qvar, ProAir, montelukast sodium.

Key Analysis Provided

  • Brand/therapy usage across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)
    • Treatment Algorithms: Claims Data Analysis in Adult Asthma (US) February 2019

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Shubhendu Ghosh, PhD
  • Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.

Purchase Report

Recent reports:
You may also be interested in: